References
- Kraemer M, Weber R, Herold M, et al. Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth. Mult Scler 2015;21(11):1473–5.
- Calabrese LH, Dodick DW, Schwedt TJ, et al. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med 2007;146(1):34–44.
- Mehdi A, Haij-Ali RA. Reversible cerebral vasoconstriction syndrome: a comprehensive update. Curr Pain Headache Rep 2014;18(9):443.
- Ducros A, Fiedler U, Porcher R, et al. Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome frequency, features, and risk factors. Stroke 2010;41:2505–11.
- Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427(6972):355–60.
- Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33(2):91–101.
- Alewijnse AE, Peters SL, Michel MC, et al. Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br J Pharmacol 2004;143(6):666–84.
- Alewijnse AE, Peters SLM. Sphingolipid signalling in the cardiovascular system: good, bad or both? Eur J Pharmacol 2008;585(2–3):292–302.
- Gilenya® [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corp; 2016
- Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355(11):1124–40.
- Schwarz A, Korporal M, Hosch W, et al. Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. Neurology 2010;74(24):2022–4.
- Leypoldt F, Munchau A, Moeller F, et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 2009;72(11):1022–4.